Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Salarius Pharmaceuticals Inc SLRX

Healthcare Biotechnology
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and... see more

Recent & Breaking News (NDAQ:SLRX)

Salarius Pharmaceuticals to Participate in BIO International Convention 2022

GlobeNewswire June 9, 2022

Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

GlobeNewswire May 18, 2022

Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results

GlobeNewswire May 12, 2022

Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration

GlobeNewswire May 11, 2022

Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress

GlobeNewswire May 5, 2022

Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering

GlobeNewswire April 22, 2022

Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results

GlobeNewswire March 10, 2022

Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company Progress

GlobeNewswire March 3, 2022

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference

GlobeNewswire February 17, 2022

Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference

GlobeNewswire February 8, 2022

Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program

GlobeNewswire February 3, 2022

Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC

GlobeNewswire January 13, 2022

Salarius Pharmaceuticals to Present at Virtual H.C. Wainwright BioConnect, Participate in Virtual Biotech Showcase and BIO Partnering @ JPM During "J.P. Morgan Week 2022"

GlobeNewswire January 6, 2022

Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial

GlobeNewswire December 29, 2021

Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum

GlobeNewswire December 15, 2021

Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference

GlobeNewswire November 29, 2021

Salarius Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

GlobeNewswire November 4, 2021

Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress

GlobeNewswire October 26, 2021

Salarius Pharmaceuticals and Nationwide Children's Hospital Disclose Research Findings from Presentation at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 7, 2021

Salarius Pharmaceuticals to Present at the 2021 BioFuture Conference

GlobeNewswire October 5, 2021